Please see attached herewith the Transcript of the Earnings Call held on May 20, 2026, with Analysts/Investors to discuss the Audited Financial Results (both Standalone & Consolidated) ....
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HCG reported FY26 revenues of INR 2,545 crore (15% YoY growth) with adjusted EBITDA of INR 471.1 crore (19% YoY growth, margins at 18.5%). Q4 revenues stood at INR 652 crore with margins expanding 90 bps to 19.2%. The company completed a INR 425 crore rights issue and divested its fertility business Milann to Inviga Healthcare Fund at an enterprise valuation of INR 63 crore. Net debt reduced to 1.4x from 2.2-2.3x previously. Management targets 15% revenue growth for FY27 with 100 bps EBITDA margin expansion. Plans include 200+ brownfield beds over 24 months and approximately 1,000 total bed additions by FY30 (400 greenfield, 600 brownfield) across 10-12 evaluated cities. West and East clusters identified for maximum margin expansion potential.
HCG's focus on profitable growth, debt reduction, and oncology focus through Milann divestment is positive for shareholders. The rights issue strengthens the balance sheet for expansion while the margin expansion strategy targeting 100 bps improvement signals operational efficiency focus. Growth visibility remains intact with multiple levers including new facilities, clinician additions, and Day-Care center expansion.